"I want to share my story and help others like myself living with MPN. MPN Research Foundation has been that source of community support for my family and I as we learn to deal with living with a disease on a daily basis."

News

Help me find

MPD doctors discuss benefits of 2 JAK2 Inhibitors

December 2010

Drs. Ayalew Tefferi and Animesh Pardanani presented data at ASH on the benefits of two drugs currently in clinical trials: TG101348 and CYT387. TG101348 is currently being tested in myelofibrosis patients and has been shown to reduce constitutional symptoms as well as reduction in spleen size and JAK burden in many of the patients. CYT387 is also being tested in myelofibrosis patients and also reduces spleen size as well as helps with symptoms, but also works to reduce the affects of anemia in myelofibrosis patients.

For the original article click here.

 

Your donation goes a long way.

Learn more about how you can help support the MPN Research Foundation and the impact your contributions can make.

Donate Now
 
 
 

Subscribe

Want to learn more about the MPN Research Foundation? Sign up for our Newsletter and Research Alerts!

Newsletter Signup

 
 

Connect with Us

MPN Research Foundation wants to hear from you. Connect with us through our social networks or send us an email.

Email Facebook Twitter LinkedIn